Intracellular delivery of paclitaxel using oil-free, shell cross-linked HSA - Multi-armed PEG nanocapsules

Jeong Yu Lee; Ki Hyun Bae; Jee Seon Kim; Yoon Sung Nam; Tae Gwan Park

doi:10.1016/j.biomaterials.2011.07.063

Intracellular delivery of paclitaxel using oil-free, shell cross-linked HSA - Multi-armed PEG nanocapsules

Jeong Yu Lee, Ki Hyun Bae, Jee Seon Kim, Yoon Sung Nam, Tae Gwan Park

Research output: Contribution to journal › Article › peer-review

48 Scopus citations

Abstract

Various approaches to increase the solubility of water-insoluble anti-cancer drugs in aqueous formulations have been undertaken with the aim of treating solid tumors through intravenous drug administration. Nanoscale drug carriers are particularly attractive for cancer therapy because of their passive targeting effect to enhance the therapeutic efficacy of drugs. Here we introduce an oil-free, shell cross-linked nanocapsule as an efficient intracellular delivery system for paclitaxel. The nanocapsules are prepared by emulsifying amine-reactive six-arm-branched polyethylene glycol (PEG) in dichloromethane into aqueous solution of human serum albumin (HSA), followed by cross-linking at the organic/aqueous interface. Paclitaxel is successfully incorporated into the HSA/PEG nanocapsules having a spherical shape with an average diameter of about 280 nm. In several types of cells, the surface modification of nanocapsules with a cell-penetrating peptide, Hph1, greatly facilitates cellular uptake and apoptosis-inducing effects of paclitaxel. Furthermore, the targeted anti-tumor activities of the paclitaxel-loaded nanocapsules in a mouse tumor model suggest that the shell cross-linked nanocapsules are very promising oil-free nanoscale delivery vehicles for water-insoluble anti-cancer agents.

Original language	English
Pages (from-to)	8635-8644
Number of pages	10
Journal	Biomaterials
Volume	32
Issue number	33
DOIs	https://doi.org/10.1016/j.biomaterials.2011.07.063
State	Published - Nov 2011
Externally published	Yes

Funding

The late Professor Tae Gwan Park supervised the overall work as a principal investigator. All co-authors deeply appreciate his invaluable contribution and educational efforts. This research was financially supported from the Ministry of Health, Welfare and Family Affairs and the Ministry of Education, Science and Technology (Republic of Korea) through Basic Science Research Program (2010-0027955), the World Class University project, and the National Research Laboratory program. We thank Dr. Earl Choi and Prof. Won-il Jeong in the Graduate School of Medical Science and Engineering for their kind assistance in animal experiments.

Funders	Funder number
World Class University
Ministry of Health and Welfare
Ministry of Education, Science and Technology	2010-0027955

Keywords

Cell-penetrating peptide
Drug delivery system
Human serum albumin
Nanocapsule
Paclitaxel

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.biomaterials.2011.07.063

Cite this

@article{33181c9fbcba4dbca55f79202261553d,

title = "Intracellular delivery of paclitaxel using oil-free, shell cross-linked HSA - Multi-armed PEG nanocapsules",

abstract = "Various approaches to increase the solubility of water-insoluble anti-cancer drugs in aqueous formulations have been undertaken with the aim of treating solid tumors through intravenous drug administration. Nanoscale drug carriers are particularly attractive for cancer therapy because of their passive targeting effect to enhance the therapeutic efficacy of drugs. Here we introduce an oil-free, shell cross-linked nanocapsule as an efficient intracellular delivery system for paclitaxel. The nanocapsules are prepared by emulsifying amine-reactive six-arm-branched polyethylene glycol (PEG) in dichloromethane into aqueous solution of human serum albumin (HSA), followed by cross-linking at the organic/aqueous interface. Paclitaxel is successfully incorporated into the HSA/PEG nanocapsules having a spherical shape with an average diameter of about 280 nm. In several types of cells, the surface modification of nanocapsules with a cell-penetrating peptide, Hph1, greatly facilitates cellular uptake and apoptosis-inducing effects of paclitaxel. Furthermore, the targeted anti-tumor activities of the paclitaxel-loaded nanocapsules in a mouse tumor model suggest that the shell cross-linked nanocapsules are very promising oil-free nanoscale delivery vehicles for water-insoluble anti-cancer agents.",

keywords = "Cell-penetrating peptide, Drug delivery system, Human serum albumin, Nanocapsule, Paclitaxel",

author = "Lee, {Jeong Yu} and Bae, {Ki Hyun} and Kim, {Jee Seon} and Nam, {Yoon Sung} and Park, {Tae Gwan}",

year = "2011",

month = nov,

doi = "10.1016/j.biomaterials.2011.07.063",

language = "English",

volume = "32",

pages = "8635--8644",

journal = "Biomaterials",

issn = "0142-9612",

publisher = "Elsevier",

number = "33",

}

TY - JOUR

T1 - Intracellular delivery of paclitaxel using oil-free, shell cross-linked HSA - Multi-armed PEG nanocapsules

AU - Lee, Jeong Yu

AU - Bae, Ki Hyun

AU - Kim, Jee Seon

AU - Nam, Yoon Sung

AU - Park, Tae Gwan

PY - 2011/11

Y1 - 2011/11

N2 - Various approaches to increase the solubility of water-insoluble anti-cancer drugs in aqueous formulations have been undertaken with the aim of treating solid tumors through intravenous drug administration. Nanoscale drug carriers are particularly attractive for cancer therapy because of their passive targeting effect to enhance the therapeutic efficacy of drugs. Here we introduce an oil-free, shell cross-linked nanocapsule as an efficient intracellular delivery system for paclitaxel. The nanocapsules are prepared by emulsifying amine-reactive six-arm-branched polyethylene glycol (PEG) in dichloromethane into aqueous solution of human serum albumin (HSA), followed by cross-linking at the organic/aqueous interface. Paclitaxel is successfully incorporated into the HSA/PEG nanocapsules having a spherical shape with an average diameter of about 280 nm. In several types of cells, the surface modification of nanocapsules with a cell-penetrating peptide, Hph1, greatly facilitates cellular uptake and apoptosis-inducing effects of paclitaxel. Furthermore, the targeted anti-tumor activities of the paclitaxel-loaded nanocapsules in a mouse tumor model suggest that the shell cross-linked nanocapsules are very promising oil-free nanoscale delivery vehicles for water-insoluble anti-cancer agents.

AB - Various approaches to increase the solubility of water-insoluble anti-cancer drugs in aqueous formulations have been undertaken with the aim of treating solid tumors through intravenous drug administration. Nanoscale drug carriers are particularly attractive for cancer therapy because of their passive targeting effect to enhance the therapeutic efficacy of drugs. Here we introduce an oil-free, shell cross-linked nanocapsule as an efficient intracellular delivery system for paclitaxel. The nanocapsules are prepared by emulsifying amine-reactive six-arm-branched polyethylene glycol (PEG) in dichloromethane into aqueous solution of human serum albumin (HSA), followed by cross-linking at the organic/aqueous interface. Paclitaxel is successfully incorporated into the HSA/PEG nanocapsules having a spherical shape with an average diameter of about 280 nm. In several types of cells, the surface modification of nanocapsules with a cell-penetrating peptide, Hph1, greatly facilitates cellular uptake and apoptosis-inducing effects of paclitaxel. Furthermore, the targeted anti-tumor activities of the paclitaxel-loaded nanocapsules in a mouse tumor model suggest that the shell cross-linked nanocapsules are very promising oil-free nanoscale delivery vehicles for water-insoluble anti-cancer agents.

KW - Cell-penetrating peptide

KW - Drug delivery system

KW - Human serum albumin

KW - Nanocapsule

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=80052970758&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2011.07.063

DO - 10.1016/j.biomaterials.2011.07.063

M3 - Article

C2 - 21864901

AN - SCOPUS:80052970758

SN - 0142-9612

VL - 32

SP - 8635

EP - 8644

JO - Biomaterials

JF - Biomaterials

IS - 33

ER -

Intracellular delivery of paclitaxel using oil-free, shell cross-linked HSA - Multi-armed PEG nanocapsules

Abstract

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this